Hookipa Pharma (NASDAQ:HOOK – Get Free Report) had its price objective cut by investment analysts at JMP Securities from $50.00 to $23.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ target price would indicate a potential upside of 270.37% from the company’s previous close.
A number of other analysts have also commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $50.00 price target on shares of Hookipa Pharma in a report on Tuesday, May 21st. HC Wainwright boosted their target price on Hookipa Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th.
Read Our Latest Report on Hookipa Pharma
Hookipa Pharma Trading Down 1.7 %
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $2.40. Hookipa Pharma had a negative net margin of 88.73% and a negative return on equity of 33.33%. The firm had revenue of $36.60 million for the quarter, compared to analyst estimates of $3.20 million. During the same quarter in the previous year, the firm posted ($2.70) earnings per share. On average, analysts predict that Hookipa Pharma will post -3.45 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Hookipa Pharma stock. Virtu Financial LLC purchased a new position in shares of Hookipa Pharma Inc (NASDAQ:HOOK – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 43,021 shares of the company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Featured Stories
- Five stocks we like better than Hookipa Pharma
- How to Choose Top Rated Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Stock Dividend Cuts Happen Are You Ready?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.